AR110904A1 - ANTI-TGF-b ANTIBODIES AND ITS USE - Google Patents
ANTI-TGF-b ANTIBODIES AND ITS USEInfo
- Publication number
- AR110904A1 AR110904A1 ARP180100118A ARP180100118A AR110904A1 AR 110904 A1 AR110904 A1 AR 110904A1 AR P180100118 A ARP180100118 A AR P180100118A AR P180100118 A ARP180100118 A AR P180100118A AR 110904 A1 AR110904 A1 AR 110904A1
- Authority
- AR
- Argentina
- Prior art keywords
- tgf
- antibody
- seq
- conditions
- antibodies
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La solicitud proporciona un anticuerpo pan-TGF-b mejorado para el tratamiento de afecciones que están mediadas por TGF-b, incluyendo enfermedades autoinmunitarias, afecciones fibróticas, y cánceres. También se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1. Reivindicación 1: Un anticuerpo monoclonal aislado que se une específicamente a TGF-b1, TGF-b2, y TGF-b3 humano, que comprende las regiones determinantes de la complementariedad de cadena pesada (CDR) 1 - 3 de SEQ ID Nº 1 y las CDR1 - 3 de cadena ligera de SEQ ID Nº 2, en donde el anticuerpo comprende una región constante de IgG4 que tiene una prolina en la posición 228 (numeración UE).The application provides an improved pan-TGF-b antibody for the treatment of conditions that are mediated by TGF-b, including autoimmune diseases, fibrotic conditions, and cancers. Uses and uses of the antibody are also provided together with other immunomodulatory agents such as an anti-PD-1 antibody. Claim 1: An isolated monoclonal antibody that specifically binds TGF-b1, TGF-b2, and human TGF-b3, comprising the heavy chain complementarity determining (CDR) regions 1-3 of SEQ ID No. 1 and Light chain CDR1-3 of SEQ ID No. 2, wherein the antibody comprises a constant region of IgG4 having a proline at position 228 (EU numbering).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762448800P | 2017-01-20 | 2017-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110904A1 true AR110904A1 (en) | 2019-05-15 |
Family
ID=66669189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100118A AR110904A1 (en) | 2017-01-20 | 2018-01-18 | ANTI-TGF-b ANTIBODIES AND ITS USE |
Country Status (2)
Country | Link |
---|---|
KR (3) | KR102568885B1 (en) |
AR (1) | AR110904A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2976359B2 (en) * | 2013-03-20 | 2022-03-23 | Genzyme Corporation | Methods for treating osteogenesis imperfecta |
TWI681969B (en) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
EP3277716B1 (en) * | 2015-04-03 | 2020-06-24 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
-
2018
- 2018-01-18 AR ARP180100118A patent/AR110904A1/en unknown
- 2018-01-19 KR KR1020197024043A patent/KR102568885B1/en active IP Right Grant
- 2018-01-19 KR KR1020247028042A patent/KR20240133763A/en active Application Filing
- 2018-01-19 KR KR1020237027750A patent/KR102699080B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR102568885B1 (en) | 2023-08-21 |
KR20190105077A (en) | 2019-09-11 |
KR102699080B1 (en) | 2024-08-27 |
KR20240133763A (en) | 2024-09-04 |
KR20230124768A (en) | 2023-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20200734A1 (en) | ANTI-TGF-BETA ANTIBODIES AND THEIR USE | |
AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
PE20191208A1 (en) | ANTI-CD73 ANTIBODIES AND USES OF THEM | |
AR104213A1 (en) | ANTI-BODIES ANTI-CD38 AS THERAPEUTIC AGENTS | |
PE20190398A1 (en) | NEW ANTIBODIES THAT SPECIFICALLY BIND AND USES OF THE ZIKA VIRUS EPITHOPES | |
PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
EA201991729A1 (en) | ANTIBODIES TO TGF-BETA AND THEIR APPLICATION | |
ECSP17005649A (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
PE20200384A1 (en) | METHOD OF MANUFACTURE OF BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES | |
UY36692A (en) | ANTI-CD40 ANTIBODIES AND USES OF THE SAME | |
MX2018008934A (en) | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same. | |
AR101875A1 (en) | ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME | |
PE20211887A1 (en) | ANTIGENIC CHIMERICAL RECEPTOR (CAR) THAT INCLUDES A DOMAIN OF BINDING TO ANTIGENS, WHICH SELECTIVELY JOINES THE CONSTANT REGION OF THE TCR BETA 1 (TRBC1) OR TRBC2 OF T CELLS | |
EA202091130A1 (en) | LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN | |
PE20161389A1 (en) | ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA | |
EA202090800A1 (en) | NEW ANTI-CD3-EPSILON ANTIBODIES | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
AR096601A1 (en) | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE | |
UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
CL2020002600A1 (en) | Anti-programmed death antibody-ligand 1 and its use | |
MX2020008122A (en) | Anti-pd-1 antibodies. | |
AR119507A1 (en) | TRISPECIFIC ANTI-PD-1/LAG3/TIGIT ANTIBODIES AND BISPECIFIC ANTI-PD-1/LAG3 ANTIBODIES | |
AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
EA201992460A1 (en) | BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION | |
CL2022000230A1 (en) | Anti-ms4a4a antibodies and methods of using the same |